摘要
目的观察阿替普酶对急性脑梗死的临床疗效及其安全性。方法选择2008年3月～2010年12月35例急性脑梗死患者(治疗组)使用阿替普酶(rt-PA)静脉溶栓治疗,以同期非溶栓治疗的具有相同条件的患者30例作为对照组。两组患者治疗前、后6h、24h、7d进行神经功能缺损评分。结果治疗组与对照组的疗效比较差异有统计学意义,治疗组的NIHSS6h、24h、7d评分减少程度高于对照组,差异有统计学意义(P<0.05)。结论只要严格掌握溶栓治疗时间窗、适应证、禁忌证,阿替普酶静脉溶栓治疗急性脑梗死是安全、有效的,并能显著改善患者神经功能缺损症状。
Objective To study the clinical effect of alteplase on the patients with acute cerebral infarction.Methods Intravenous thrombolytic therapy was performed on 35 patients as thrombolysis-treated group（treatment group） and meanwhile 30 patients as control group with the similar conditions to the thrombolysis-treated group were managed without intravenous thrombolysis.NIHSS score in different time before and after treatment were measured.Results The therapeutic efficacy between the two groups was obviously difference,the reducing degree of NIHSS score was significantly higher in the treatment group than in the control group（P0.05）.Conclusion Provided therapeutic time window、indications and contraindications were well controlled,intravenous thrombolytic therapy with alteplase is safe and effective in the treatment of acute cerebral infarction and can significantly improve neurologic deficits symptoms of the patients.
出处
《当代医学》
2011年第16期144-145,共2页
Contemporary Medicine
关键词
急性脑梗死
阿替普酶
静脉溶栓
Acute cerebral infarction
Alteplase
Intravenous thrombolysis
